HRMY - Harmony Biosciences preannounces record quarterly revenue for Q2 2026, reaffirms full-year 2026 revenue guidance, and announces CFO t
HRMY - Harmony Biosciences preannounces record quarterly revenue for Q2 2026, reaffirms full-year 2026 revenue guidance, and announces CFO transition Harmony Biosciences - reiterates fy2026 net product revenue guidance of $1B to $1.04B - CFO Glenn reicin steps down effective July 16, 2026 - Appoints Stephen mollichella as interim Principal financial officer
HRMY - Harmony Biosciences preannounces record quarterly revenue for Q2 2026, reaffirms full-year 2026 revenue guidance, and announces CFO transition Harmony Biosciences - reiterates fy2026 net product revenue guidance of $1B to $1.04B - CFO Glenn reicin steps down effective July 16, 2026 - Appoints Stephen mollichella as interim Principal financial officer